Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00487539 · BASELINE

Baseline characteristics

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis · Source last updated 2014-02-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      331
    2. group Id
      BG001
      value
      72
    3. group Id
      BG002
      value
      331
    4. group Id
      BG003
      value
      331
    5. group Id
      BG004
      value
      1065
    units
    Participants
groups
  1. description
    Placebo subcutaneous injection (given under the skin by way of a needle) matched to golimumab administered at Week 0 and Week 2.
    id
    BG000
    title
    Placebo
  2. description
    Golimumab 100 milligram (mg) subcutaneous injection was administered at Week 0 and dose was decreased to 50 mg at Week 2.
    id
    BG001
    title
    Golimumab 100 mg -> 50 mg
  3. description
    Golimumab 200 mg subcutaneous injection was administered at Week 0 and dose was decreased to 100 mg at Week 2.
    id
    BG002
    title
    Golimumab 200 mg -> 100 mg
  4. description
    Golimumab 400 mg subcutaneous injection was administered at Week 0 and dose was decreased to 200 mg at Week 2.
    id
    BG003
    title
    Golimumab 400 mg -> 200 mg
  5. description
    Total of all reporting groups
    id
    BG004
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          13.04
          value
          39
        2. group Id
          BG001
          spread
          12.19
          value
          40.9
        3. group Id
          BG002
          spread
          13.54
          value
          40
        4. group Id
          BG003
          spread
          13.75
          value
          40.7
        5. group Id
          BG004
          spread
          13.37
          value
          40
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    Years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          156
        2. group Id
          BG001
          value
          32
        3. group Id
          BG002
          value
          151
        4. group Id
          BG003
          value
          130
        5. group Id
          BG004
          value
          469
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          175
        2. group Id
          BG001
          value
          40
        3. group Id
          BG002
          value
          180
        4. group Id
          BG003
          value
          201
        5. group Id
          BG004
          value
          596
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      331
    2. group Id
      BG001
      value
      72
    3. group Id
      BG002
      value
      331
    4. group Id
      BG003
      value
      331
    5. group Id
      BG004
      value
      1065
    units
    Participants
groups
  1. description
    Placebo subcutaneous injection (given under the skin by way of a needle) matched to golimumab administered at Week 0 and Week 2.
    id
    BG000
    title
    Placebo
  2. description
    Golimumab 100 milligram (mg) subcutaneous injection was administered at Week 0 and dose was decreased to 50 mg at Week 2.
    id
    BG001
    title
    Golimumab 100 mg -> 50 mg
  3. description
    Golimumab 200 mg subcutaneous injection was administered at Week 0 and dose was decreased to 100 mg at Week 2.
    id
    BG002
    title
    Golimumab 200 mg -> 100 mg
  4. description
    Golimumab 400 mg subcutaneous injection was administered at Week 0 and dose was decreased to 200 mg at Week 2.
    id
    BG003
    title
    Golimumab 400 mg -> 200 mg
  5. description
    Total of all reporting groups
    id
    BG004
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          13.04
          value
          39
        2. group Id
          BG001
          spread
          12.19
          value
          40.9
        3. group Id
          BG002
          spread
          13.54
          value
          40
        4. group Id
          BG003
          spread
          13.75
          value
          40.7
        5. group Id
          BG004
          spread
          13.37
          value
          40
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    Years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          156
        2. group Id
          BG001
          value
          32
        3. group Id
          BG002
          value
          151
        4. group Id
          BG003
          value
          130
        5. group Id
          BG004
          value
          469
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          175
        2. group Id
          BG001
          value
          40
        3. group Id
          BG002
          value
          180
        4. group Id
          BG003
          value
          201
        5. group Id
          BG004
          value
          596
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice